Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 8/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17150677 | 0.87 | HPGD (0.62) | HPGDRECQLHSD17B10PTPN2PTPN1 | |
| SCHEMBL4512366 | 0.83 | HPGD (0.62) | HPGDRECQLHSD17B10PTPN2PTPN1 | |
| SCHEMBL22719731 | 0.83 | HPGD (0.62) | HPGDRECQLHSD17B10PTPN2PTPN1 | |
| SCHEMBL16291661 | 0.83 | HPGD (0.62) | HPGDRECQLHSD17B10PTPN2PTPN1 | |
| SCHEMBL43357 | 0.83 | HPGD (0.66) | HPGDRECQLHSD17B10PTPN2PTPN1 | |
| SCHEMBL16230337 | 0.82 | HPGD (0.60) | HPGDRECQLHSD17B10PTPN2PTPN1 | |
| SCHEMBL28195249 | 0.81 | HPGD (0.68) | HPGDRECQLHSD17B10PTPN2PTPN1 | |
| SCHEMBL5425897 | 0.81 | HPGD (0.68) | HPGDRECQLHSD17B10PTPN2PTPN1 | |
| SCHEMBL9933876 | 0.80 | RECQL (0.56) | HPGDRECQLHSD17B10PTPN2PTPN1 | |
| Acetic Acid SCHEMBL7381337 | 0.80 | HPGD (0.62) | HPGDRECQLHSD17B10PTPN2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1641771-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | UCB PHARMA SA (BE) | 2008-10-15 | — | — | EP | disclosed |
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-12-07 | — | — | US | disclosed |
| EP-1648868-B1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R&D LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CELLTECH R&D LIMITED (GB) | 2006-10-26 | — | — | US | disclosed |
| EP-1641771-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | Celltech R & D Limited (GB) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004113312-A1 | HYDROXAMATE SULFONAMIDES AS CD23 SHEDDING INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276507-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD2, CD22, NEU3 | HPGD 1520/4885RECQL 4706/4885HSD17B10 2783/4885 |
| US-20060241118-A1 | Hydroxamate sulfonamides as cd23 shedding inhibitors | CD22, CD2, DPP3 | HPGD 1399/4885RECQL 4704/4885HSD17B10 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.